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Abstract
Background: The incidence of non-Hodgkin’s lymphoma has increased over recent years. The exact etiology of
lymphoma remains unknown. Ultraviolet light exposure has been associated with the development of internal
lymphoid malignancies and some reports suggest that it may play a role in the development of lymphoma in
humans. Here we describe the characterization and progression of lymphoma in p53 heterozygous mice exposed
to UVB irradiation.
Methods: UVB-irradiated p53
+/- mice developed enlargement of the spleen. Isolated spleen cells were transplanted
into Rag deficient hosts. The UV-induced tumor cells were analyzed by flow cytometry. The tumor cells were
tagged with GFP to study their metastatic potential. SKY and karyotypic analysis were carried out for the detection
of chromosomal abnormalities. Functional assays included in vitro class switch recombination assay,
immunoglobulin rearrangement assay, as well as cytokine profiling.
Results: UVB-exposed mice showed enlargement of the spleen and lymph nodes. Cells transplanted into Rag
deficient mice developed aggressive tumors that infiltrated the lymph nodes, the spleen and the bone marrow.
The tumor cells did not grow in immune competent syngeneic C57Bl/6 mice yet showed a modest growth in
UV-irradiated B6 mice. Phenotypic analysis of these tumor cells revealed these cells are positive for B cell markers
CD19
+, CD5
+, B220
+, IgM
+ and negative for T cell, NK or dendritic cell markers. The UV-induced tumor cells
underwent robust in vitro immunoglobulin class switch recombination in response to lipopolysaccharide.
Cytogenetic analysis revealed a t(14;19) translocation and trisomy of chromosome 6. These tumor cells secret IL-10,
which can promote tumor growth and cause systemic immunosuppression.
Conclusion: UV-irradiated p53
+/- mice developed lymphoid tumors that corresponded to a mature B cell
lymphoma. Our results suggest that an indirect mechanism is involved in the development of internal tumors after
chronic exposure to UV light. The induction of B cell lymphoma in UV-irradiated p53 heterozygous mice may
provide a useful model for lymphoma development in humans.
Background
The incidence of non-Hodgkin’s lymphoma has
increased over recent years, an increase that cannot be
totally explained by improvements in diagnosis or
reporting. The exact etiology of lymphoma remains
unknown but viral infection, chronic antigen stimula-
tion, and/or immunosuppression, either primary or
acquired immunodeficiency, may all contribute to the
occurrence of lymphoma [1]. Some reports suggest that
exposure to the UV radiation in sunlight may play a
role in the development of lymphoma in humans [2].
This conclusion is based primarily on epidemiological
data showing a geographic correlation between sunlight
exposure and lymphoma incidence (i.e., a latitude gradi-
ent) [3-7]. However, not all the reports supported a link
between sunlight exposure and lymphoma development
[8-11], some findings indicate an inverse association
between the solar UVB exposure and the occurrence of
non-Hodgkin lymphoma [12-15]. The rise in lymphoma
i n c i d e n c ep a r a l l e l st h ed r a m a t i cr i s ei nm e l a n o m ai n c i -
dence, and patients with non-Hodgkin’s lymphoma or
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developing skin cancer [16,17].
Studies with experimental animals suggest a strong
correlation between UV exposure and lymphoma devel-
opment [18,19]. Animal experiments offer the distinct
advantage of controlled irradiation with defined UV
light sources, without the complications that arise from
exposure to any other environmental carcinogens or
toxins, nor the complication of recall bias. We pre-
viously reported that UV irradiation augments lymphoid
malignancies in mice with one functional copy of wild-
type p53. In that study we demonstrated that UV irra-
diated p53 heterozygous mice developed lymphoid
tumors at a much higher rate (88% of irradiated mice
developed tumors) than found in un-irradiated animals
(6% spontaneous tumor rate). Sequencing data indicated
that the UV-irradiated p53
+/- mice retained the non-
mutated p53 allele, suggesting loss of heterozygosity did
not play a role in the induction of this tumor [19].
The biological effects of UV exposure are well known.
UVB, wavelengths in the 280-320 nm range of the solar
s p e c t r u m ,c a ni n d u c eaw i d ev a r i e t yo fa d v e r s ee f f e c t s .
Chief among them are sunburn, inflammation, premature
ageing of the skin, the induction of non-melanoma skin
cancer and the induction of immune suppression
(reviewed in [20]). UVA (320-400 nm) has been sug-
gested to be important in melanoma induction [21]. It is
clear that the adverse effects of UV exposure are not
solely limited to the skin; how UV exposure influences
lymphoma development in humans, however, is still far
from being completely understood. Here we analyzed the
UV-induced lymphoid malignancies that arise in mice
with one functional copy of p53. We have previously ana-
lyzed UV-induced lymphoid malignancies by histopatho-
logical examination of formalin-fixed tissues. To be able
to study the biology of the tumors we needed to generate
tumor cell lines from UV-irradiated p53
+/- mice. We
exposed p53
+/- mice to solar simulated UV radiation for
a period of 30 weeks and then injected spleen cells into
immune deficient Rag2
-/- mice. We generated a number
of transplantable tumor cells lines, some of which were
further adapted to grow in vitro. We found that UV-irra-
diation of p53
+/- mice resulted in the induction of B-cell
tumors (CD5
+,C D 1 9
+,B 2 2 0
+,I g M
+) that grew progres-
sively in immune deficient mice, but not in immune com-
petent animals, and grew at low rate in UV-irradiated
C57Bl/6 mice. We suggest the induction of B cell lympho-
mas by UV radiation in p53
+/- mice may serve as a useful
animal model for lymphoma development.
Methods
Mice
Specific pathogen-free p53 knockout mice were back-
crossed onto a C57Bl/6 background [19]. Specific
pathogen-free Rag2
-/- mice were obtained from Dr. Fred
Alt (Howard Hughes Medical Institute, Children’sH o s -
p i t a l ,B o s t o n ,M A ) .A l lm i c ew e r eh o u s e di nap a t h o -
gen-free barrier facility. The Institutional Animal Care
and Use Committee approved all procedures.
UV irradiation
A 1000 W Xenon UV solar simulator equipped with a
Schott WG-320 atmospheric attenuation filter and a
visible/infrared band-pass filter (Oriel, Stratford, CT)
was used to irradiate the mice. The intensity and spec-
tral output was measured using an Optronics Model
OL-754 scanning spectrophotometer (Optronics Lab,
Orlando, FL) [22]. Seventeen p53 heterozygous mice
were divided in two groups of 8 and 9 mice each for
UV irradiation. The mice were shaved on the dorsal
skin and were kept individually in a Plexiglas container;
then, they were irradiated three times a week during
10-15 minutes for a period of 30 weeks. During this
procedure the mice remained conscious all the time.
Transplantation
Cells (2.5 × 10
6) from enlarged spleens of the irradiated
mice were injected subcutaneously into each flank of a
Rag2
-/-, wild type and/or UV irradiated (10 kJ/m
2,3
times per week for 12 weeks) C57Bl/6 mouse. Mice
were monitored daily for tumor development. The
tumors were excised and analyzed by flow cytometry
and histopathology.
Flow cytometric analysis
Cell surface molecule expression was analyzed by flow
cytometry using a BD FACS-Calibur (BD Biosciences, San
Jose, CA). Fluorescently-labeled monoclonal antibodies to
mouse CD1d, CD3, CD4, CD5, CD8a, CD11b, CD16/32,
CD19, CD23, CD25, CD38, CD40, CD43, CD44, CD45R/
B220, CD49b, CD62L, CD80, CD86, CD90, CD117,
CD123, CD127, CD138, IgM and IgD, GR-1 were pur-
chased from commercial sources (Becton-Dickinson,
Mountain View, California, and eBioscience, San Diego,
California).
In vitro class switch recombination assay
The cells were stimulated with lipopolysaccharide (LPS)
(Sigma, St. Louis, MO), IL-4 (10ng/ml) plus CD40L (10
ng/mL), and a combination of CD40L/TGFb (10 ng/mL
each, all from PeproTech Rocky Hill, NJ). The cells
were analyzed 96 hours later by flow cytometry using a
BD FACS-Calibur or BD LSR II (Becton-Dickinson,
Mountain View, California).
Southern blotting analysis
High molecular weight DNA samples were prepared
from the tumor, digested with EcoR1 and hybridized
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Page 2 of 10with a JH probe using Gene images AlkPhos Direct
Labeling and detection System (Amersham Biosciences,
Buckinghamshire, UK).
Cytogenetic analysis
Tumor cells were cultured in the presence of Colcemid.
Metaphases were analyzed with trypsin-Giemsa stain
and with whole chromosome painting probes (Carlsbad,
CA, USA). To analyze potential chromosomal transloca-
tions, the metaphases were also used for spectral karyo-
typing analysis (SKY; Applied Spectral Imaging, Inc.
Vista, CA).
Cell culture and lentiviral vector transduction
Tumor cells (1 × 10
5) were incubated with lentiviral
vectors. The number of green fluorescent protein (GFP)
positive cells was analyzed by flow cytometry at multiple
time points after transduction. Highly expressing GFP
bearing cells were isolated by cell sorting (BD FACS-
Aria, BD Biosciences, San Jose, CA).
Cytokine determination
Cytokine secretion of the tumor cells into the superna-
tant fluid was measured by the multiplexed mouse cyto-
kine Ten-Plex Antibody Bead system (BIOSOURCE,
Camarillo, CA) and the Luminex 100 fluorescence
detection system (Austin, TX). Cytokines analyzed by
this system include: IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-
10, IL-12, GM-CSF, Interferon-gamma and TNF-alpha.
Results
UV exposure induced non-skin tumors in p53
heterozygous mice
To obtain a maximal probability of tumor development
[19], we exposed 17 p53 heterozygous mice to 10 kJ/m
2
of UVB radiation, 3 times a week, during 30 weeks. At
the end of this period, the animals were sacrificed. Ana-
lysis of necropsy showed severe skin irritation at the
irradiated area and 15 out of 17 irradiated mice devel-
oped splenomegaly and half of which also developed
enlarged mesenteric lymph nodes. To assess their
tumorigenic potential, cell suspensions (approximately
2.6 × 10
6) were prepared from the enlarged spleens and
lymph nodes, and were injected subcutaneously into an
immune deficient Rag2
-/- mouse. When tumors were
evident they were excised and used for cell culture and
histology (data not shown). A cell suspension sample
from a tumor was re-injected into 3-4 Rag2
-/- mice.
While the cells transplanted into the Rag2
-/- mice
showed progressive growth, these cells were unable to
grow ex vivo after the first in vivo passage. However, we
were able to establish a cell line capable of growing in
v i t r oa f t e rt w ot ot h r e ea d ditional passages through
Rag2
-/- mice. At each successive passage through Rag2
-/-
mice the latency period decreased, and after three pas-
sages subcutaneous tumors were noticeable at one-week
post injection. This procedure was carried out several
times and in all cases tumors were consistently gener-
ated in Rag2
-/- mice. However, only cells originated
from the enlarged spleens were able to grow progres-
sively in vivo and in vitro, whereas cells originated from
the enlarged mesenteric lymph nodes were not able to
survive in vitro. We were able to originate three cell
lines that were able to grow in vivo and in vitro.
UV-exposed mice developed a matured B-cell tumor
Phenotypic analysis was carried out using flow cytome-
try on the tumor cells that grew in Rag2
-/- mice. All the
cells were included in this analysis, and we avoided
selecting the cells by size. These tumor cells were posi-
tive to the surface markers CD19, B220, CD5 and IgM,
and also expressed the co-stimulatory molecules CD80,
CD86 as well as CD117 (Figure 1A). The cells were
negative for the T cell specific markers CD3, CD4, CD8
and Th1.2; and were negative for the markers normally
found on NK cells (NK1.1, CD49b) or dendritic cells/
macrophages (CD11b). Moreover, the cells were also
negative to surface markers expressed on immature B
cells (CD43, BP-1, CD127). Southern blotting analysis
showed a rearrangement of the immunoglobulin heavy
chain in the DNA of the tumor cells as compared to the
non-lymphoid DNA obtained from a Rag mouse, further
supporting the conclusion that the tumor cells are
indeed B-cells (Figure 1B). Using G-banding on meta-
phase spreads from the tumor cells we found a chromo-
somal translocation on chr14, and a small acrocentric
chromosome. Spectral karyotyping (SKY) analysis con-
firmed the translocation was between the chromosomes
14 and 19 in all three cell lines studied (Figure 2 shows
the representative results of one cell line). The translo-
cated region was located proximal to the telomere on
chromosome 19. SKY analysis also showed a trisomy on
chromosome 19 (data not shown), with a likely com-
plete translocation to chromosome 14. SKY analysis also
showed a trisomy on chromosome 6 (Figure 2). The
recurrent chromosomal translocation in all three cell
lines strongly implies a role in tumorigenesis. However,
the molecular details regarding the potential genes
involved remain to be determined.
The UV transformed B cells are stable and undergo
robust class switch recombination (CSR)
To further explore whether the properties of these
tumor B cells are typical of the B cell lineage, we exam-
ined their ability to undergo CSR in response to various
stimuli [23]. The transformed B cells were kept in cul-
ture for 3-5 days and analyzed for spontaneous CSR.
The cells with low spontaneous switching to IgG1, IgG3
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tion; the sub-cloned cells were stimulated with 25, 50
and 100 ng/mL of LPS. These experiments were per-
formed at least six times. As shown in Figure 3A, LPS
induced a robust CSR in these cells in a dose-dependent
fashion from IgM to IgG2b at frequencies up to 53%.
However, modest CSR levels were observed after these
transformed B cells were stimulated with IL-4 and
CD40L or CD40L and TGFb, with frequencies of 19%
to IgG1 and 29% to IgA, respectively (Figure 3B). The
robustness of class switch recombination confirms the
mature B cell phenotype of the transformed B cells, and
the spontaneous CSR may be the result of a deregulated
CSR enzymatic mechanism in this tumor cells [24].
The UV-induced tumor B cells are immunogenic
One of the hallmarks of UV-induced skin tumors is the
fact that they are highly antigenic since they are recog-
nized and destroyed by a normal immune system,
therefore these cells only grow progressively in immune-
deficient mice [25]. In addition, UV-induced tumors will
grow in mice exposed to a subcarcinogenic dose of UV
radiation. This is due to the fact that UV exposure acti-
vates the induction of T regulatory cells that control the
growth of UV-induced tumors in the UV-irradiated host
[26,27]. To determine the growth patterns of the UV-
induced B cell tumor and determine its antigenicity, the
transformed B cells were injected into three groups of
mice, normal immune-competent C57BL/6 mice,
C57BL/6 mice exposed to a chronic course of UV radia-
tion (10 kJ/m
2, 3 times a week for 12 weeks), and
immune-deficient Rag2
-/- mice (Table 1). Progressive
tumor growth was only noted when the lymphoma cells
were injected into the Rag2
-/- recipients (100% tumor
incidence), significantly lower tumor incidence occurred
when the cells were transplanted into wild-type mice
(7%, p < 0.0001 vs. Rag2
-/- control, Fisher exact test).
Lower but not significant tumor growth was noted in
Figure 1 Tumors that grow progressively in the Rag2
-/- mice show a B cell phenotype. A. Increased forward and side scatter was used to
gate out the large tumor cells, and they were then stained with a variety of makers to determine their cell surface phenotype. B. Southern
blotting indicates that the UV-induced B cells tumors have a rearranged immunoglobulin heavy gene. DNA was isolated from two variants of
UVBL-1 (Tr-1 and Tr-12). Both variants expressed a re-arranged IgM heavy gene compared to genomic DNA isolated from non-lymphoid tissue
(mouse tail skin).
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injection of the lymphoma cells (13%, p < 0.0001 vs.
Rag2
-/- control, Fisher exact test). These data indicate
that like UV-induced skin tumors the UV-induced
tumor B cells are antigenic, but unlike UV-induced skin
tumors, these cells are not recognized by UV-induced T
regulatory cells.
The UVB induced p53 heterozygous B lymphoma cells are
metastatic
UV-transformed B cells that resulted from exposing p53
heterozygous mice to UVB light were transfected with a
vector expressing green fluorescent protein (GFP). The
cells were sorted for both CD19 and GFP. Approximately
1×1 0
7 CD19/GFP double positive tumors cells were
injected subcutaneously into 10 Rag2
-/- mice. Tumor
development was assessed in these animals and the
tumor bearing Rag2
-/-mice were sacrificed at various time
points after the injection. Flow cytometry was utilized to
determine the numbers of GFP/CD19 double positive
cells in various lymphoid tissues (Figure 4). Cells from
the spleen and bone marrow of normal Rag2
-/- mice were
used as control. CD19
+ cells were absent in all lymphoid
tissues of the non-injected Rag2
-/- mice (Figure 4A, D,
G). The CD19
+,G F P
+ cells were only found in the sub-
cutaneous tumor 4 days post injection. On day 11 these
cells were found in the draining lymph nodes (Figure 4B
& 4C), but were absent in the spleen or bone marrow.
Two populations of CD19
+ cells were found in the lymph
nodes (Figure 4C), one was negative for GFP (45.3%), and
the second was positive for GFP (54.7%). These results
suggested that although our vector was “leaky”, and since
Rag2
-/- mice do not have any CD19 cells in their lymph
nodes, the UV-transformed B cells metastasized to the
lymph nodes after 11 days post implantation. The meta-
static cells not only persisted in the lymph nodes at day
18 (data not shown), but were also found metastasized to
the spleen (Figure 4 E & 4F). The metastatic cells were
still detected in the spleen and lymph nodes at 27 days
post implantation, and during this period these cells were
also detected in the bone marrow (Figure 4H & 4I). To
determine whether the metastatic cells had migrated to
other organs, we analyzed cell suspensions from the thy-
mus, lung, liver and kidney, and found no evidence of
these cells in any of these organs. These results indicate
that the UV-induced B cell tumor cells were capable to
metastasize to the bone marrow, spleen and lymph
nodes, but not to any other tissue.
A
B
C
 1 2 3 4 5
6 7 8 9 10
11 12 13 14 15
16 17 18 19 X
m1
14
19
Figure 2 Analysis of chromosomal abnormalities in the UV-induced B cell lymphoma. A. G banding of metaphase spreads was prepared
and indicated two abnormalities, an increase in size of chromosome 14, suggesting a translocation, and a small acrocentric chromosome (M2). B
and C: Multi-color FISH confirms a translocation between chromosomes 14 and 19 and trisomal chromosome 6.
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To establish cytokine profiles, supernatant from cultured
UV-induced tumor B cells were collected at various time
points after the initiation of culture (24 to 72 hours).
The production of a variety of cytokines by the cultured
cells was analyzed using the Luminex system. Our
results showed that the un-stimulated tumor cells only
secreted IL-10 when cultured for 24 and 72 h in com-
plete RPMI medium (Figure 5). These results indicate
that IL-10 producing cells may have an increased advan-
tage to promote their metastasis to other organs as
observed in our analyses.
Discussion
We characterized the lymphoid tumors that arise in UV-
irradiated p53
+/- mice. No evidence of T cell tumors was
found in this study. This may reflect the different way in
which this study and our previous work was carried out.
Our observation that UV exposure induced T cell tumors
was based on a retrospective study in which histopatholo-
gical analyses of paraffin-embedded tissue was used to
determine the phenotype of the tumor [19]. Here, we
generated tumors by injecting spleen cells isolated from
UV-irradiated p53 heterozygous mice into Rag2-/- mice.
The tumor cells were subjected to several passages in
vivo until we were able to generate stable tumor cell lines
that could grow in Rag2
-/- mice and in culture. From
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Figure 3 UVBL-1 cells exhibit a robust CSR in response to LPS stimulation. A. Flow cytometry analysis of untreated, 25 and 100 ng/ml LPS
treated UVBL-1 cells undergo class switch recombination to IgG2b; B. Untreated, IL-4
+CD40L and CD40L
+TGFb treated UVBL-1 cells class switch
to IgG1 and IgA respectively.
Table 1 Growth of UV-induced B cell tumors in
immune-deficient but not wild type mice
Recipient Mice* Number of
mice
Number with
tumor
p‡
Rag2
-/- 15 15 _
C57Bl/6 15 1 0.0001
UV-irradiated C57Bl/6† 15 2 0.0001
*2×1 0
6 tumor cells were injected into the subcutaneous space of the
recipient mice. Tumor growth was monitored daily. Mice were sacrificed when
the tumor volume exceeded 1 cm
2.
† 10 kJ/m
2 UVB radiation, 3x per week for 12 weeks prior to tumor
transplantation.
‡ p values determined by Fisher’s exact test comparing tumor growth in
immune deficient Rag2
-/- vs. growth in wild type or UV-irradiated wild type
mice.
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Page 6 of 10these experiments we obtained three cell lines that grew
in vivo but only one was also able to grow in vitro. It is
possible that our “culture” favored the growth of B cells
but not T cells. In one series of experiments, we pheno-
typed each successive in vivo passage, and in one of the
earlier passages, we noted the presence of some T cell
receptor positive cells (which by definition must be of
tumor origin since the Rag2
-/- mice cannot rearrange the
T cell receptor). These cells were purified by cell sorting
and then injected into Rag2
-/- mice. No T cell tumors
developed. This suggests that abnormal cells may have
been present, but were not capable of growing progres-
sively upon further passage in vivo.
It is interesting to compare our results to those pre-
viously published by MacPherson and colleagues [28]. In
their study, transgenic mice were constructed with a
point mutation in the murine p53 gene (serine 23 was
replaced with alanine). These mice, which displayed
defective apoptosis, had a reduced life span and most
developed tumors. However, unlike the tumor spectrum
found in p53
-/- mice (predominately thymic lymphomas
and sarcomas), the most common tumors found in
homozygous p53 Ser23 mice were of B cell origin. The
authors suggest that the long latency period to tumori-
genesis in the p53 Ser23 mice provides the time
required to acquire additional genetic changes to
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Figure 4 Metastatic behavior of the CD19
+ B cell lymphoma.C D 1 9
+ UVBL-1 cells were transfected with GFP and injected subcutaneously
into the flanks of Rag2
-/- mice. Metastasis was analyzed 11, 18 and 27 days post injection. A: Background staining in the lymph nodes of Rag2
-/-
mice; isotype staining in red; CD19 staining in blue. B: CD19 staining in the lymph nodes of Rag2
-/- mice injected with UVBL-1; isotype staining
in red; CD19 staining in blue. C: Double staining showing expression of CD19 by GFP positive cells Lymph node metastasis was analyzed 11
days post implantation. D: Background staining in the spleens of Rag2
-/- mice. E: CD19 staining in the spleens of Rag2
-/- mice injected with
UVBL-1. F: Double staining showing expression of CD19 by GFP positive cells. Bone marrow metastasis was analyzed 27 days post injection. G:
Background staining in bone marrow of Rag2
-/- mice. H: CD19 staining in the spleen of mice injected with UVBL-1. I. Double staining showing
expression of CD19 by GFP positive cells. Bone marrow metastasis was analyzed 27 days post injection. All other tissues examined (thymus, lung,
live kidney) were negative.
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Page 7 of 10develop B cell tumors. We also note a long latency per-
iod for tumor development in our system, and as men-
tioned below, we suggest UV-induced inflammation may
play a significant role.
Chromosomal analysis revealed a t(14:19) translocation,
which may play a role in UV-induced lymphomagenesis.
However, to the best of our knowledge, a similar translo-
cation has not been reported in lymphoma in the mouse.
We analyzed the translocated region of chromosome 19
and found that this region contains the apoptotic genes
Caspase 7 and programmed cell death 4, and the DNA
cross-link repair 1a gene (SNM1a) which is involved in G1
cell cycle checkpoint downstream of ATM [29]. We sus-
pect the t(14;19) translocation contributes to the deregula-
tion of these and other genes and probably plays an
important role in the oncogenic process in these cells. In
addition, trisomy of chromosome 6 has been reported in
chemically induced malignant skin tumors in TG.AC
mice, which carry the v-Ha-ras transgene [30], and a simi-
lar imbalance has been reported in both benign and malig-
nant skin tumors in the mouse [31]. Therefore, it is likely
that the trisomy of chromosome 6 observed in our model
is the result of the chronic exposure to UVB and probably
it is also a contributing factor to the transformation of the
UV-induced tumor B cells. We are currently exploring the
possible deregulated oncogenes/tumor suppressors in
these tumor cell lines.
What are the signals involved in the maintenance and
proliferation of these tumors? Simple loss of heterozygos-
ity does not appear to be an adequate explanation because
when the B cell lymphomas were sequenced, we found
they retained a normal wild-type p53 allele (data not
shown). We favor the view that the immune suppression
and chronic inflammation i n d u c e db yU Ve x p o s u r ea r e
involved. As noted above, the B cell lymphomas are highly
antigenic. From our previous study we know that p53
+/-
mice are immune competent and UV exposure will induce
immune suppression in these mice [19], so it is reasonable
to assume that the immune suppression induced by
c h r o n i cU Ve x p o s u r ep r o v i d e saw i n d o wt h a tw i l la l l o w
these antigenic cells to grow in the UV-irradiated p53
+/-
mice. While it has been argued that an inverse association
of sun exposure with NHL risk is related to the protective
effects of vitamin D synthesis by UV radiation [15,32-36];
we know that the induction of systemic immune suppres-
sion following UV exposure of the skin is associated with
the release of immune modulatory factors and immune
suppressive cytokines. These may have direct relevance to
the results reported here. The first is IL-10. UV-irradiation
of the skin induces keratinocytes to secrete IL-10 [37,38]
and IL-10 can be found in the serum of UV-irradiated
mice [39]. Moreover, IL-10 promotes the growth and dif-
ferentiation of human B cells [40] and has been shown to
promote the growth of B cell lymphomas [41,42]. Serum
IL-10 is also considered to be a negative prognostic indica-
tor for the survival of patients with non-Hodgkin’sl y m -
phoma [43]. The second is platelet-activating factor (PAF).
PAF is a phospholipid that plays a primary role in the
induction of inflammation. As the name implies PAF acti-
vates a wide variety of cells, including platelets, monocytes,
mast cells and polymorphonuclear leukocytes [44]. PAF is
secreted by epidermal cells almost immediately following
UV exposure [45] and serves as a transcriptional activator
for a variety of genes including cyclooxygenase (COX)-2,
IL-6 and IL-10 [46,47]. PAF also plays an essential role in
UV-induced immune suppression. Blocking the binding of
PAF to its receptor, with a series of selective PAF receptor
antagonists, blocks UV-induced transcription of COX-2
and IL-10 and blocks UV-induced immune suppression
[47]. Normal and leukemic B cells express the PAF recep-
tor [48,49] and PAF has been shown rescue B cells from
apoptosis [50].
Our results suggest the following scenario: the loss of
a single p53 allele predisposes the B cells for transfor-
mation. Long-term chronic UV exposure then induces
the release of inflammatory mediators by irradiated ker-
atinocytes that promote tumor development. For exam-
ple, UV-irradiated keratinocytes secrete macrophage
migration inhibitory factor (MIF) [51], which can inhibit
p53 tumor suppressor activity [52], thus resulting in a
functional “loss of heterozygosity” in the UV-irradiated
p53
+/- mice. Other UV-induced mediators of inflamma-
tion, such as PAF, may also play important roles in the
process. First, PAF induces chronic inflammation, which
appears to be associated with the induction of non-
Hodgkin’s lymphoma [53]. Second, PAF binds to recep-
tors on B cells and protects them from apoptosis. PAF
0
200
400
600
24 48 72
Time in culture (h)
IL-10
 (pg/ml/10 6  cells)
Figure 5 IL-10 secretion by the UV-induced B cell lymphomas.
The cells were grown in vitro without any further stimulation.
Supernatants from duplicates of three Petri dishes were collected at
24, 48 and 72 hours and were analyzed individually. Each column
represents the average in IL-10 concentration of 6 samples. The only
cytokine detected in the supernatant fluid was IL-10. The bar
indicates the standard error of the mean (SEM).
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is important because the expression of either prostaglan-
din E2 or IL-10 has been associated with a poor prog-
nosis in lymphoma patients [43,54]. In addition, both
are immune suppressive, and we suggest UV-induced
immune suppression (mediated by PAF, prostaglandin
and IL-10), protects the developing antigenic B cell lym-
phoma from immune destruction. Our data provide a
link between chronic UV exposure and the incidence of
internal tumors in the 53 heterozygous background.
Although there is no development of skin tumors in
p53 heterozygous mice, somehow chronic UV exposure
develops cellular transformation away form the site of
exposure by a mechanism still under investigation.
Conclusion
We characterized the lymphoid tumors that arise in UV-
irradiated p53
+/- mice. The tumors were CD5
+, CD19
+ B
cell lymphomas that showed robust CSR capacity upon
stimulation. The lymphomas secreted Il-10, which might
help in the promotion of metastasis and lymphoma
growth. Chromosomal analysis revealed a t(14;19) trans-
location and trisomy of chromosome 6. Sequencing ana-
lysis indicated that the remaining p53 allele was intact,
suggesting that an indirect mechanisms is involved in
the generation of these tumors. In the future, we intend
to try several therapies to block the induction of the
UV-induced B cell lymphomas in p53
+/- mice including
PAF receptor antagonist PCA-4248 treatment [55] or
anti-IL-10 antibody therapy [56]. If successful, it may
provide support for the hypothesis that the association
between sunlight exposure and the development of non-
Hodgkin’sl y m p h o m ai nh u m a n si sa s s o c i a t e dw i t h
chronic inflammation and the modulation of immune
function by chronic UV exposure.
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